Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

NCT00631800 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Staphylococcal Sepsis

Interventions

DRUG: Pagibaximab (formerly BSYX-A110)

Sponsor

Biosynexus Incorporated

Collaborators

[object Object]